What is NovoCure's EPS (diluted)?

NovoCure (NVCR) reported EPS (diluted) of -$0.62 in Q1 2026.

How has NovoCure's EPS (diluted) changed year-over-year?

NovoCure's EPS (diluted) decreased by 100.0% year-over-year, from -$0.31 to -$0.62.

What is the long-term trend for NovoCure's EPS (diluted)?

Over 4 years (2021 to 2025), NovoCure's EPS (diluted) has grown at a 21.5% compound annual growth rate (CAGR), from -$0.56 to -$1.22.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

NovoCure NVCR EPS (Diluted)

EPS (Diluted) at other companies

Boston ScientificBSX

$0.90+100%

MedtronicMDT

$0.97+18.3%

Iovance Biotherapeutics, Inc.IOVA

-$0.19+47.2%

Vir Biotechnology, Inc.VIR

-$0.85+3.4%

ArriVent BioPharma, Inc.AVBP

-$0.96+49.5%

Syndax PharmaceuticalsSNDX

-$0.48+51.0%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.64B-36.7%

Enterprise value$1.59B-36.3%

P/S2.4×-1.7×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's EPS (diluted)?: NovoCure (NVCR) reported EPS (diluted) of -$0.62 in Q1 2026.
How has NovoCure's EPS (diluted) changed year-over-year?: NovoCure's EPS (diluted) decreased by 100.0% year-over-year, from -$0.31 to -$0.62.
What is the long-term trend for NovoCure's EPS (diluted)?: Over 4 years (2021 to 2025), NovoCure's EPS (diluted) has grown at a 21.5% compound annual growth rate (CAGR), from -$0.56 to -$1.22.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.